Kyowa Kirin Company Profile

What is the competitive landscape for KYOWA KIRIN

KYOWA KIRIN has two approved drugs.

There are two US patents protecting KYOWA KIRIN drugs.

There are forty-seven patent family members on KYOWA KIRIN drugs in seventeen countries and one supplementary protection certificate in one country.

Summary for Kyowa Kirin

International Patents:	47
US Patents:	2
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Kyowa Kirin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kyowa Kirin	FARESTON	toremifene citrate	TABLET;ORAL	020497-001	May 29, 1997		DISCN	Yes	No
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-002	Aug 27, 2019		RX	Yes	Yes	7,727,993		Y
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-002	Aug 27, 2019		RX	Yes	Yes	8,318,201		Y
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-001	Aug 27, 2019		RX	Yes	No	7,727,993		Y
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-001	Aug 27, 2019		RX	Yes	No	8,318,201		Y

Expired US Patents for Kyowa Kirin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kyowa Kirin	FARESTON	toremifene citrate	TABLET;ORAL	020497-001	May 29, 1997	4,696,949
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-002	Aug 27, 2019	7,541,363
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-001	Aug 27, 2019	7,541,363
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-001	Aug 27, 2019	7,727,994
Kyowa Kirin	NOURIANZ	istradefylline	TABLET;ORAL	022075-002	Aug 27, 2019	7,727,994

International Patents for Kyowa Kirin Drugs

Country	Patent Number	Estimated Expiration
Japan	WO2005030219
European Patent Office	2260850
Mexico	PA04007299
South Korea	101098209
Canada	2813048
South Korea	20100056569
South Korea	101166000

Supplementary Protection Certificates for Kyowa Kirin Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0095875	96C0029	Belgium		PRODUCT NAME: TOREMIFENE; REGISTRATION NO/DATE: EU/1/96/004/001 19960215

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Kyowa Kirin

Pharmaceutical Competitive Landscape Analysis: Kyowa Kirin – Market Position, Strengths & Strategic Insights

Last updated: January 23, 2026

Summary

Kyowa Kirin Co., Ltd. is a Japanese specialty pharma company, focusing on innovative biologics, biosimilars, and specialty therapeutics. It maintains a significant global footprint with strategic acquisitions and a diversified portfolio. This report offers an in-depth competitive analysis, evaluating Kyowa Kirin’s market position, core strengths, competitive advantages, challenges, and strategic initiatives within the broader pharmaceutical landscape.

---

What Is Kyowa Kirin’s Market Position?

Global Presence & Market Share

Region	Market Focus	Estimated Revenue (2022)	Key Competitors	Market Share Estimates*
Japan	Specialty biologics, oncology, nephrology	¥280 billion (~$2.0B)	Takeda, Daiichi Sankyo, Ono Pharma	5-8% in targeted segments
North America	Biosimilars, oncology, nephrology	~$300 million	Amgen, Pfizer, Biogen	~1% in biosimilars segment
Europe	Biosimilars, rare diseases	~$150 million	Sandoz, Biogen, Celltrion	~0.5-1%
Emerging Markets	Contract manufacturing, specialty drugs	Growing rapidly	Local innovators, global biosimilar companies	N/A

* Market share estimates are approximations based on secondary industry reports and company disclosures.

Key Drivers of Market Position

• Focused investments in biologics and biosimilars.
• Successful commercialization of flagship assets, notably Fexuprazan (acid suppressant) and Monoclonal antibodies.
• Strong presence in Japan through longstanding relationships and regulatory expertise.

---

What Are Kyowa Kirin’s Core Strengths?

1. Specialized Biologics and Biosimilars Portfolio

Product Category	Examples	Indications	Competitive Edge
Oncology (Antibodies)	Mogamulizumab (POTELIGEO®)	Cutaneous T-cell lymphoma, solid tumors	First-in-class, orphan indications
Nephrology	Nihon Kidney Disease (NKD) therapies	Anemia management in CKD	Niche focus, strong KOL network
Biosimilars	Amgevil (Filgrastim biosimilar)	Hematological disorders	Cost competitiveness, regulatory track record

2. R&D Capabilities & Innovation Pipeline

• Invests ~18% of revenues into R&D annually.
• Partnerships with academic institutions for biologics development.
• Active pipeline of phase 1 and 2 biologics targeting autoimmune diseases.

3. Regulatory & Market Access Expertise

• Decades-long experience navigating Japan’s PMDA processes.
• Early engagement strategies leading to swift approvals.
• Tailored patient access programs.

4. Strategic Acquisitions & Collaborations

Year	Acquisition/Partnership	Impact
2012	Acquisition of rights for Mogamulizumab in Japan	Accelerated oncology portfolio growth
2019	Partnership with BeiGene for PD-1 inhibitor tislelizumab	Broadened immuno-oncology access
2021	Acquisition of certain assets from Shire (now Takeda)	Strengthened specialty pipeline

---

What Are the Main Competitive Challenges and Threats?

Challenge/Threat	Details
Limited Global Scale vs. Major Multinationals	Large rivals like Pfizer, Novartis, and Roche dominate global biologics markets.
Patent Expirations & Biosimilar Competition	Biosimilar erosion of established biologics’ premiums.
Regulatory Hurdles in International Markets	Navigating diverse regulatory pathways poses market entry delays.
Competition for R&D Talent	Intense global competition for biotech scientists.
Pricing Pressures & Healthcare Cost Containment	Governments and payers seek lower biosimilar prices.

---

What Strategic Initiatives Are Kyowa Kirin Pursuing?

Portfolio Optimization & Expansion

• Increase biosimilar footprint in the US and Europe, leveraging existing manufacturing expertise.
• Develop first-in-class biologics for autoimmune and infectious diseases.

Market Penetration & Geographic Expansion

• Strengthening presence in Southeast Asia, Latin America, and Africa.
• Establishing regional partnerships to facilitate local manufacturing and distribution.

Innovation & Digital Transformation

• Implement blockchain and AI tools for drug discovery.
• Enhance real-world evidence collection to support regulatory approvals.

Collaborative Models

Approach	Focus Areas	Outcomes
Strategic Alliances	Immuno-oncology, gene therapies	Access to new modalities, risk mitigation
Public-Private Partnerships	Rare disease research, vaccine development	Accelerated development timelines

---

Comparison with Major Competitors

Aspect	Kyowa Kirin	Takeda	Sandoz (Novartis)	Amgen	Biogen
Revenue (2022)	~$2B (Japan focus)	~$30B	~$10B biosimilars	~$27B	~$11B
Focus Area	Specialty biologics, biosimilars	Broad pharmaceuticals, oncology	Biosimilars, generics	Biologics, hematology	Neurology, autoimmune
R&D Spend	~18% of revenues	~20%	Lower in biosimilars	~16%	~19%
Key Differentiator	Niche expertise, strong in Japan	Global scale, diversified	Cost leadership	Innovation pipeline	Neuroscience leadership

---

FAQs: Common Inquiries About Kyowa Kirin

1. How does Kyowa Kirin differentiate itself from larger peers?

Kyowa Kirin specializes in biologics and biosimilars with a focus on niche therapeutic areas such as oncology and nephrology. Its deep regulatory expertise in Japan offers a strategic advantage in penetrating Asian markets and tailoring products to unmet needs.

2. What are Kyowa Kirin's most successful products?

• Mogamulizumab (POTELIGEO®): A monoclonal antibody approved for skin T-cell lymphoma in Japan.
• Nihon Kidney Disease Therapies: Focused on anemia management in CKD.
• Biosimilars: Including Amgevil (Filgrastim biosimilar).

3. How is Kyowa Kirin expanding its global footprint?

Through strategic acquisitions, licensing arrangements, and partnerships—especially in biosimilars and emerging markets—it aims to supplement revenue streams beyond Japan.

4. What are the main risks facing Kyowa Kirin?

Patent expirations of key biologics, aggressive biosimilar competition, regulatory delays in new markets, and potential R&D pipeline failures.

5. What future strategic directions can enhance Kyowa Kirin’s competitive position?

• Accelerate global biosimilar development.
• Invest in innovative biologics, including cell and gene therapies.
• Strengthen partnerships, especially in emerging markets.
• Leverage digital health tools for R&D efficiency.

---

Key Takeaways

• Market Position: Kyowa Kirin holds a solid niche in Japanese specialty biologics and biosimilars, with growing international interest, especially in biosimilar development.

• Strengths: Deep regulatory expertise, innovative biologics pipeline, strategic acquisitions, and an established niche in oncology and nephrology.

• Challenges: Limited global scale compared to giants, biosimilar competition eroding legacy products, and regulatory complexity.

• Strategic Focus: Portfolio diversification into innovative biologics, increasing market penetration through partnerships, and leveraging technological innovations for R&D and commercialization.

• Business Opportunity: Capitalizing on biosimilar growth in Europe and North America, expanding into emerging markets, and pioneering next-generation biologics could position Kyowa Kirin for sustained growth in the evolving pharma landscape.

---

References

1. Kyowa Kirin Annual Report 2022.
2. IQVIA, "Global Biosimilar Market Report 2022."
3. EvaluatePharma, "Top 50 Pharma & Biotech Companies 2022."
4. Company Press Releases, Kyowa Kirin.
5. Industry Analyst Reports, 2022–2023.

---

Disclaimer: This analysis is based on publicly available information and industry estimates as of 2023. Market dynamics are subject to rapid change, necessitating ongoing review.